Both miR-15a and miR-16-1 were found to inhibit tumor survival pathways, including mitogen-activated protein (MAP)-kinases, AKT serine/threonine-protein-kinase, NF-κB-activator MAP3KIP3 and ribosomal-protein-S6 [136]. This evidence concerns the gene AKT1 and neoplasm.